Lv1
94 积分 2025-01-09 加入
Coronado CLL: A Phase Ib/II Trial of Combination Rp-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refract ory Chronic Lymphocytic Leukemia
8天前
已关闭
Coronado CLL: A Phase Ib/II Trial of Combination Rp-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refract ory Chronic Lymphocytic Leukemia
8天前
已关闭
Multi-drug delivery nanocarriers for combination therapy
2个月前
已完结
Advancements in nanotechnology for PARP inhibitor delivery: a comprehensive review of diverse nanosystems, their mechanisms, and therapeutic applications across cancer and beyond
4个月前
已完结
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway
4个月前
已完结
Prostate cancer
5个月前
已完结
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition
5个月前
已完结
Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline
5个月前
已完结
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer
5个月前
已完结
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
7个月前
已完结
皖公网安备34019202002308
